HC Wainwright Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

Lexeo Therapeutics (NASDAQ:LXEO) had its price objective lowered by investment analysts at HC Wainwright from $23.00 to $15.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 455.56% from the company’s current price.

A number of other equities analysts also recently commented on LXEO. Leerink Partners reduced their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, March 24th. Chardan Capital cut their price target on Lexeo Therapeutics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Royal Bank of Canada reduced their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, March 25th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Buy” and a consensus target price of $20.20.

Lexeo Therapeutics Stock Up 0.4%

NASDAQ:LXEO opened at $2.70 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a 1-year low of $1.45 and a 1-year high of $19.50. The company has a 50-day moving average of $3.06 and a 200 day moving average of $5.01. The firm has a market cap of $89.63 million, a PE ratio of -0.85 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19). As a group, research analysts anticipate that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC grew its holdings in Lexeo Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock worth $454,000 after purchasing an additional 31,057 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Lexeo Therapeutics by 48.3% in the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock worth $507,000 after purchasing an additional 25,089 shares in the last quarter. Rhumbline Advisers grew its stake in Lexeo Therapeutics by 19.6% during the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company’s stock worth $166,000 after buying an additional 4,127 shares during the last quarter. JPMorgan Chase & Co. increased its position in Lexeo Therapeutics by 135.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock valued at $93,000 after buying an additional 5,915 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Lexeo Therapeutics in the fourth quarter valued at about $117,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.